Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

Starting soon · Phase 3

Conditions studied: Acute Myeloid Leukemia

In brief

This study aims to compare the efficacy and safety of a shortened treatment course based on the bone marrow blast count on Day 14 versus standard treatment in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.

Key facts

Study ID: NCT07407660
Run by: Peking University People's Hospital
People needed: 250
Starts: 2026-02-01
Expected to finish: 2030-02-01
Last updated by the study team: 2026-02-12

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with newly diagnosed acute myeloid leukemia who meet the WHO 2022 criteria.
Meeting one of the following conditions:
Aged ≥ 60 years;
aged ≥ 18 years and < 60 years, with one or more of the following comorbidities that render the subject unsuitable for intensive induction therapy:
Complicated with congestive heart failure, or left ventricular ejection fraction ≤ 50%, or a history of chronic stable angina pectoris;
A history of pulmonary disease, with carbon monoxide diffusing capacity of the lung (DLCO) ≤ 65% or forced expiratory volume in 1 second (FEV1) ≤ 65%;
Creatinine clearance rate < 45 mL/min (calculated by the **Cockcroft-Gault formula**);
Total bilirubin > 1.5 × upper limit of normal;
Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≥ 2;
Any other comorbidities judged by the investigator to contraindicate intensive induction therapy.
Received induction therapy with the azacitidine plus venetoclax regimen (azacitidine for injection: 75 mg/m² subcutaneously on Days 1-7; venetoclax tablets: 100 mg on Day 1, 200 mg on Day 2, and 400 mg once daily starting on Day 3) for 12-14 days. Dose adjustment of venetoclax shall be performed if combined with strong or moderate CYP3A/P-gp inhibitors.
Completed risk stratification assessment per the ELN 2022 criteria.
Signed the informed consent form.

You may not qualify if…

Diagnosis of acute promyelocytic leukemia, AML with t(8;21)(q22;q22.1)/ RUNX1::RUNX1T1 translocation, or blast crisis of chronic myeloid leukemia (CML).
Prior treatment with venetoclax before the diagnosis of acute myeloid leukemia.
A history of allogeneic hematopoietic stem cell transplantation.
Severe hepatic or renal impairment, defined by the presence of any of the following abnormalities: aspartate aminotransferase (AST) > 2.5 × ULN; alanine aminotransferase (ALT) > 2.5 × ULN; creatinine clearance rate < 30 mL/min (calculated by the Cockcroft-Gault formula); or total bilirubin > 3 × ULN.
Presence of acute active infection requiring intravenous systemic therapy.
Presence of active malignant tumors requiring antineoplastic treatment.
Presence of active autoimmune diseases requiring treatment with prednisone ≥ 15 mg/day or equivalent doses of other glucocorticoids, or any other immunosuppressive agents.
Inability to swallow tablets, or presence of diseases significantly impairing gastrointestinal function (e.g., malabsorption syndrome, gastrectomy or enterectomy, bariatric surgery, symptomatic inflammatory bowel disease, or partial/complete intestinal obstruction).
Pregnant or lactating female subjects.
Subjects judged by the investigator to be unable to comply with the protocol due to uncontrollable medical, psychological, familial, social, or geographic conditions; or those who are unwilling or unable to follow the required procedures of the protocol.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.